BioNTech Se (NASDAQ: BNTX)
BioNTech Se Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
BioNTech Se Company Info
BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.
News & Analysis
3 No-Brainer Biotech Stocks to Buy With $200 Right Now
2 Healthcare Stocks to Buy Hand Over Fist and 1 to Avoid
Is BioNTech Stock a Buy Now?
Or is it too late to get in on the company after its coronavirus-related success?
Why BioNTech Stock Was Sinking Today
While the waning of the COVID pandemic is a positive development for the world, it's left the German biotech struggling.
Why Shares of BioNTech Rose Friday
The company released positive trial data for a non-small cell lung cancer therapy.
2 Undervalued Stocks to Buy for Potentially Massive Gains in the Next 10 Years
Both are experiencing a bit of a hangover from declining COVID-19-related sales.
Why Shares of BioNTech Slumped Monday
The company released fourth-quarter earnings.
Wall Street Thinks These 2 Undervalued Stocks Have Exceptional Growth Potential
They're both facing the same fierce headwind, and it won't be going away soon.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.